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RESEARCH ARTICLE
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Abstract
The dietary fiber guar gum has beneficial effects on obesity, hyperglycemia and hypercho-
lesterolemia in both humans and rodents. The major products of colonic fermentation of
dietary fiber, the short-chain fatty acids (SCFAs), have been suggested to play an important
role. Recently, we showed that SCFAs protect against the metabolic syndrome via a
signaling cascade that involves peroxisome proliferator-activated receptor (PPAR) γ repres-
sion and AMP-activated protein kinase (AMPK) activation. In this study we investigated the
molecular mechanism via which the dietary fiber guar gum protects against the metabolic
syndrome. C57Bl/6J mice were fed a high-fat diet supplemented with 0% or 10% of the fiber
guar gum for 12 weeks and effects on lipid and glucose metabolism were studied. We dem-
onstrate that, like SCFAs, also guar gum protects against high-fat diet-induced metabolic
abnormalities by PPARγ repression, subsequently increasing mitochondrial uncoupling
protein 2 expression and AMP/ATP ratio, leading to the activation of AMPK and culminating
in enhanced oxidative metabolism in both liver and adipose tissue. Moreover, guar gum
markedly increased peripheral glucose clearance, possibly mediated by the SCFA-induced
colonic hormone glucagon-like peptide-1. Overall, this study provides novel molecular
insights into the beneficial effects of guar gum on the metabolic syndrome and strengthens
the potential role of guar gum as a dietary-fiber intervention.
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Introduction
The growing prevalence of diseases clustered in the metabolic syndrome is accompanied by a
shift in diet in Western and developing countries from a traditional low-calorie diet with high-
fiber and low-fat content towards a high-calorie diet with low-fiber and high-fat content [1,2].
Epidemiological studies revealed an inverse correlation between dietary fiber intake and the
metabolic syndrome [3], suggesting that fiber supplementation to the diet may be beneficial.
Indeed, a variety of studies have shown that dietary fiber intervention decreased obesity and
insulin resistance in both healthy and metabolic syndrome patients (reviewed by Galisteo et al.
[1]). In randomized controlled clinical trials a 6-week supplementation of one of the most
promising fibers (guar gum) reduced fasting plasma glucose and insulin levels, and increased
insulin sensitivity in healthy and type 2 diabetes humans [4,5]. Prolonging the guar gum sup-
plementation to 8 weeks also led to a decrease in fat mass and body weight in overweight sub-
jects [6,7]. The beneficial effects of dietary fibers work through the intestinal microbiota [8].
The main products of intestinal bacterial fermentation of dietary fiber are the short-chain fatty
acids (SCFAs), of which acetate, propionate and butyrate are most abundant [9]. SCFAs have
been suggested to play a major role in the dietary fiber-induced beneficial effects. We showed
that dose-dependent effects of guar gum-supplementation on body weight and insulin sensitiv-
ity correlate with the rate of SCFA uptake by the host, but not with their cecal concentration
[10], suggesting that fiber-derived SCFAs need to be taken up to exert their full physiological
effect.
When any of the three individual SCFAs is supplied directly via the diet, they are highly effi-
cacious in protection against the high-fat diet-induced metabolic syndrome (i.e. insulin resis-
tance and obesity) [11–13]. In these studies, SCFAs had no effect on glucose tolerance. We
recently elucidated the underlying mechanism: dietary SCFAs repress peroxisome proliferator-
activated receptor (PPAR) γ expression, subsequently increasing mitochondrial uncoupling
protein (UCP) 2 expression and AMP/ATP ratio, leading to the activation of AMP-activated
protein kinase (AMPK) and culminating in enhanced oxidative metabolism in both liver and
adipose tissue [13].
In this study we investigate whether guar gum exerts its effects on body weight, insulin sen-
sitivity and glucose tolerance via the same signaling cascade as SCFAs, as should be expected
when the produced SCFAs are the main molecular mediators of the guar gum-induced effects.




The national and institutional guidelines for the care and use of animals were followed, and the
experimental procedures were reviewed and approved by the Ethics Committees for Animal
Experiments of the University of Groningen, The Netherlands (ethics registration code 5887).
All efforts were made to minimize suffering.
Animals and Experimental Design
Male C57Bl/6J mice (Charles River, L’Arbresle Cedex, France), 2 months of age, were housed
in a light- and temperature-controlled facility (lights on 6:30 a.m. to 6:30 p.m., 21°C) and had
free access to water and food. They were fed a high-fat semi-synthetic diet (D12451, Research
Diet Services, Wijk Bij Duurstede, The Netherlands), which (unlike very similar diets from
other suppliers) contained 10% corn starch. In the experimental groups 10% (w/w) guar gum
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(ViscogumTM MP 41230, Cargill, United States) replaced the equivalent amount of corn starch.
All analyses were done in eight mice per group, unless indicated otherwise.
Plasma and tissue sampling
Mice were fasted from 6–10 a.m. Blood glucose concentrations were measured using a Euro-
Flash meter (Lifescan Benelux, Belgium). Mice were subsequently sacrificed by cardiac punc-
ture under isoflurane anesthesia. DPP IV inhibitor (DPP4, Millipore) was added, blood was
centrifuged (4000 x g for 10 min at 4°C) and plasma was stored at -80°C. Liver was quickly
removed, snap-frozen in liquid nitrogen and stored at -80°C. Epididymal fat pads were
weighed. Cecal content and cecum were quickly removed, snap-frozen in liquid nitrogen and
stored at -80°C. Plasma NEFA concentrations were determined using a commercially available
kit (Roche Diagnostics, Germany). Plasma insulin (ALPCO Diagnostics, United States), PYY
(ALPCO Diagnostics, United States) and GLP-1 levels (Merck Millipore, United States) were
determined using ELISA and HOMA-IR was calculated (IR = fasting insulin mU/L x fasting
glucose mM 22.5). Hepatic TG content was determined using a commercially available kit
(Roche) after lipid extraction [14].
Lipogenesis was determined from the incorporation of [1-13C]-acetate into palmitate by
providing 2% (w/v) [1-13C]-acetate in drinking water for 24h as described previously [15].
Fatty acid ß-oxidation capacity was measured in fresh liver and adipose homogenates accord-
ing to Hirschey et al. [16]. Briefly, tissue was homogenized in sucrose/Tris/EDTA buffer, incu-
bated for 30 min in the reaction mixture (pH 8.0) containing [1-14C]palmitic acid, and trapped
[14C]CO2 was measured. Adenine nucleotide concentrations were determined by HPLC
according to Miller et al. [17].
Indirect calorimetry
Oxygen consumption, energy expenditure, respiratory exchange ratio (RER), food intake, and
activity patterns were measured simultaneously for six mice per group using the Comprehen-
sive Laboratory Animal Monitoring System and Software (TSE Systems GmbH, Germany).
The energy balance was determined by measuring the energy content [18] of diet and dried,
homogenized feces using a bomb calorimeter (CBB 330, standard benzoic acid 6320 cal g-1,
BCS-CRM no.90N).
Glucose and insulin tolerance
Whole body glucose tolerance was determined by intraperitoneal injection of 2 g glucose per
kg body weight after an overnight fast of 9h. Whole body insulin tolerance was measured by
intraperitoneal injection of insulin (NovoRapid) at 0.75 units/kg body weight after a 4h fast.
Hyperinsulinemic-euglycemic clamp studies were performed as previously described [19].
Oxygen consumption rates in liver mitochondria
Mitochondria were isolated from fresh liver tissue according to Mildaziene et al. [20]. The rates
of oxygen consumption in isolated liver mitochondria were measured at 37°C using a two-
channel high-resolution Oroboros oxygraph-2k (Oroboros, Innsbruck, Austria) with palmi-
toyl-CoA and malate as substrates in mitochondrial respiration medium [21]. Maximal ADP-
stimulated oxygen consumption (state 3) was achieved by adding 1.5 U ml-1 hexokinase,
12.5 mM glucose and 1 mM ATP. The resting state oxygen consumption rate (state 4) was
determined after blocking ADP phosphorylation with 1.25 μM carboxyatractyloside. The
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respiratory control ratio (RCR) was calculated by dividing the oxygen consumption rate in
state 3 by the oxygen consumption rate in state 4.
Determination of SCFA concentrations
Cecal concentrations of SCFAs were measured as previously described [22]. In short, cecum
content was centrifuged and 25 μl of supernatant was spiked with 25 μl of internal standard
(17.3 mM hydroxyisocapronic acid) and 5 μl of 20% 5-sulfosalicyclic acid. After a 10 min cen-
trifugation the supernatant was acidified with 2.5 μl 37% HCl and SCFA were extracted with 2
ml diethylether. Derivatization was performed overnight with 500 μl supernatant and 50 μl of
N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA). SCFAs were measured in
an Agilent 5975 series GC/MSD (Agilent Technologies). The gas chromatograph was equipped
with a ZB-1 column (Phenomenex). Mass spectrometry analysis was performed by electron
capture negative ionization with methane as the moderating gas.
Cecal SCFA infusion experiments
Mice were fed the HFD without guar gum for 6 weeks. Cecal SCFA infusions were performed
as described previously [22]. Briefly, mice were equipped with a permanent cecum catheter
and allowed a recovery period of at least 5 days. On the day of the experiment, the mice were
individually housed and fasted from 6:00 to 10:00 a.m. All infusion experiments were per-
formed in conscious, unrestrained mice. Four different groups of each 8 mice received a
140 mM phosphate-buffered saline (140 mMNaCl, 10 mM sodium phosphate at pH 5.8), a
140 mM sodium acetate (S2889; Sigma), a 140 mM sodium propionate (P1880; Sigma) or a
140 mM sodium butyrate (303410; Sigma) solution infused via the cecum catheter at a rate of
0.2 ml/h for 6h. The infusion rate of SCFA was based on the recommended intake of dietary
fiber for humans of 38 g/day/human, which results in approximately 380 mmol SCFAs/day/
human [23,24]. When calculated for mice, this corresponds to 170 μmol SCFAs/day/mouse. By
infusing 140 mM SCFA directly into the cecum at a rate of 0.2 ml/h for 6h, a total amount of
168 μmol SCFA was given per mouse. After 6h of infusion, animals were terminated by cardiac
puncture under isoflurane anesthesia. Cecum was removed quickly, freeze-clamped, and stored
at -80°C. Blood was centrifuged (4000 x g for 10 min at 4°C) and plasma was stored at -80°C.
Gene expression levels and immunoblot analysis
RNA was extracted frommouse livers using Tri reagent (Sigma-Aldrich, St. Louis, MO) and con-
verted into cDNA by a reverse transcription procedure using M-MLV and random primers
according to the manufacturer’s protocol (Sigma-Aldrich). For quantitative PCR (qPCR), cDNA
was amplified using the appropriate primers and probes. Taqman RT-PCR primer and probe
were used to determine mRNA for MCT-1 (Mm01315398_m1), SMCT-1 (Mm00520629_m1),
Ffar2 (Mm02620654_s1), Ffar3 (Mm02621638_s1), PYY (Mm00520716_g1) and GLP-1
(Mm01269055_m1). mRNA levels were calculated relative to 36b4 (Mm00725448_s1) expres-
sion and normalized for expression levels of mice fed the control diet.
For immunoblot analysis, whole-cell lysate was prepared in lysis buffer from six mice per
group and the protein concentrations were determined using the BCA Protein Assay kit (Pierce).
Individual samples were mixed with loading buffer, heated for 5 min at 96°C and subjected to
SDS-PAGE. Antibodies and their sources were AMP kinase (AMPK, no. 2532S; Cell Signaling)
phosphorylated AMPK (pAMPK Thr172, no. 2531; Cell Signaling), acetyl CoA carboxylase
(ACC, no. 3676P; Cell Signaling), phosphorylated ACC (pACC S79, no. 31931; Abcam), uncou-
pling protein 2 (UCP2, no. 6525; Santa Cruz), peroxisome proliferator-activated receptor γ
(PPARγ, no. 2435; Cell Signaling) and fatty acid synthase (FASN, no. 3180; Cell Signaling).
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ß-actin (no. 2066; Sigma) was used as the loading control. Finally, horseradish peroxidase-conju-
gated anti-rabbit from donkey (Amersham Pharmacia Bioscience) or horseradish peroxidase-
conjugated anti-goat from donkey (Dako, Glostrup, Denmark) and SuperSignal West Pico
Chemiluminescent Substrate System (Pierce) were used. The immunoblots were analyzed by
densitometry using Image Lab software (Bio-Rad).
Statistics
All data are presented as mean values ± SEM. Statistical analysis was assessed by Mann-Whit-
ney U-test or one-way ANOVA using the Tukey test for post-hoc analysis. Statistical signifi-
cance was reached at a p value below 0.05.
Results
Guar gum protects against high-fat diet-induced obesity and insulin
resistance
To examine the effects of guar gum during the development of the metabolic syndrome,
C57Bl/6J mice were fed a semi-synthetic high-fat diet (HFD) supplemented with 0 or 10% guar
gum for 12 weeks. As expected, HFD induced body weight (BW) gain, while guar gum supple-
mentation attenuated the increase in BW (Fig 1A) and concomitantly reduced the mass of
white adipose tissue (WAT) (Fig 1B). There was no difference in liver weight to body weight
ratio between the groups (Fig 1C). Guar gum increased the cecal SCFA concentrations as well
as the mRNA expression of the cecal SCFA transporter SMCT-1, while MCT-1 was not
changed significantly (Fig 1D and 1E, respectively). To investigate the whole-body effect of
guar gum on energy metabolism, the mice were subjected to indirect calorimetry. The reduced
BW gain of guar gum-fed mice was not due to reduced food intake, as guar gum-fed mice had
similar intake (S1 Fig). Actually, energy intake and uptake increased when normalized for BW
(Fig 1F). Furthermore, guar gum did not affect the activity pattern of mice (Fig 1G), indicating
that the lower BW on HFD was not due to different physical activity either. Rather, the pheno-
type was explained by enhanced energy expenditure (Fig 1H). Mice fed guar gum displayed a
shift towards increased fatty acid oxidation, as indicated by higher O2 consumption rates and
lower respiratory exchange ratio (RER) values (Fig 1I and 1J, respectively).
Guar gum enhances oxidative metabolism via the same signaling
cascade as SCFAs
In a previous study we demonstrated—by using selective PPARγ activators and repressors in
vitro and organ-specific PPARγ knock-out mice in vivo—that adipose and hepatic PPARγ are
critical mediators of the beneficial effects of SCFA on the metabolic syndrome, with clearly dis-
tinct and complementary roles [13]. Specifically, we showed that dietary SCFAs act through
repression of PPARγ expression, subsequently increasing mitochondrial UCP2 expression and
AMP/ATP ratio, leading to the activation of AMPK and culminating in enhanced oxidative
metabolism in both liver and adipose tissue [13]. Here, we wondered if guar gum acts through
the same signaling cascade as dietary SCFAs [13].
Indeed also guar gum supplementation decreased expression of PPARγ and increased the
expression of UCP2 in both liver and adipose tissue (Fig 2A). UCP2 uncouples mitochondrial
oxidative phosphorylation, and consistently guar gum caused a significant increase of the rest-
ing respiration rate (state 4) and a 1.5-fold decrease of the respiratory control ratio in isolated
liver mitochondria (Fig 2B and 2C). Unfortunately, the low amount of mitochondria in WAT
[25] precluded direct measurements of oxygen consumption in the latter tissue. Consistently
Guar Gum Protects against the Metabolic Syndrome through SCFAs
PLOSONE | DOI:10.1371/journal.pone.0136364 August 20, 2015 5 / 14
with the increased mitochondrial uncoupling, the AMP/ATP ratio was increased in both liver
and adipose tissue upon guar gum feeding (Fig 2D). The AMP/ATP ratio is a sensitive reflec-
tion of the metabolic state of the cell and a direct activator of AMPK [26]. Indeed, phosphoryla-
tion of AMPK and its downstream target acetyl-coenzyme A carboxylase (ACC) was increased
after guar gum-feeding (Fig 2E). Total AMPK expression was not affected in liver and adipose
tissue, whereas total ACC levels were similar in liver tissue but increased in adipose tissue in
guar gum-fed mice (Fig 2E). However, in both liver and adipose tissue the pAMPK/AMPK and
pACC/ACC ratio were significantly increased upon guar gum feeding (Fig 2F). Increased phos-
phorylation of AMPK indirectly decreases expression of fatty acid synthase (FASN) [27,28],
which we also observed in the guar gum-supplemented mice (Fig 2E). Phosphorylation of ACC
inactivates the enzyme and thereby decreases the concentration of its product malonyl-CoA.
Malonyl-CoA is a substrate for fatty-acid synthesis and an inhibitor of carnitine-palmitoyl
transferase 1, a main controlling enzyme of miotochondrial fatty-acid β-oxidation. Together,
this resulted in a decrease in lipogenesis and increase in lipid oxidative capacity in both liver
and adipose tissue in guar gum-fed mice (Fig 2G and 2H). Consequently, hepatic triglycerides
and plasma NEFA concentrations decreased upon guar gum feeding (Fig 2I and 2J).
In conclusion, dietary guar gum induced the same signaling cascade in liver and adipose tis-
sue as recently described for dietary SCFAs [13], as should be expected if SCFAs are the main
molecular mediators of the guar gum-induced effects.
Fig 1. Guar gum protects against dietary-induced obesity. (A) Body weight evolution was monitored for 12 weeks. (B-C) White adipose tissue to body
weight ratio and liver weight to body weight ratio after 12 weeks on diet. (D) Cecal SCFA concentrations were determined by GC/MS after 12 weeks on diet.
(E) Cecal mRNA expression of genes involved in SCFA transport was assed via qPCR after 12 weeks on diet. (F) Energy balance was determined by
measuring the energy content of the diet and dried homogenized feces after 10 weeks on diet. Uptake is defined as the difference between intake and output.
(G-J) Total activity, energy expenditure, VO2 and RER were evaluated using indirect calorimetry data after 10 weeks on diet. Values are presented as
mean ± SEM for n = 7–8; *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0136364.g001
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Guar gum improves peripheral glucose and insulin handling
In agreement with our previous results [10], fasting plasma glucose and insulin concentrations,
and thereby HOMA-IR levels, were significantly lower in guar gum-supplemented mice (Fig
3A–3C). Glucose disposal upon insulin delivery was slightly increased and glucose tolerance
was markedly enhanced in guar gum-fed mice (Fig 3D and 3E). To further investigate the
improved glucose and insulin handling, hyperinsulinemic-euglycemic clamp (HIEC) studies
under matched insulin exposure were conducted as described previously [19]. Under basal
conditions, guar gum supplementation resulted in decreased glucose levels (Fig 4A). During
hyperinsulinemic conditions, the glucose-infusion rate was adjusted to keep the same euglyce-
mic state as under basal conditions (Fig 4A). The glucose-infusion rate required for maintain-
ing euglycemia (a measure of whole-body insulin sensitivity) was approximately 2.5-fold
higher in guar gum-supplemented mice compared to control mice (Fig 4B). Although there
Fig 2. Guar gum decreases lipogenesis and increasesmitochondrial fatty-acid oxidation in liver and adipose tissue. (A) PPARγ and UCP2
expression in liver and adipose tissue were analyzed by western blot of mice 12 weeks on diet. Quantification is shown in the upper panel. (B-C) After 12
weeks on diet, liver mitochondria were isolated and maximal ADP-stimulated oxygen consumption (i.e. state 3) and resting state oxygen consumption (i.e.
state 4) were determined using palmitoyl CoA and malate as substrates. (D) AMP to ATP ratios in liver and adipose tissue were determined by HPLC after 12
weeks on diet. (E) pAMPK, AMPK, pACC, ACC and FASN expression in liver and adipose tissue were analyzed by western blot of mice 12 weeks on diet.
Quantification is shown in the right panel. (F) Relative phosphorylation levels were calculated by the ratio of pAMPK/AMPK and pACC/ACC and normalized
for control. (G-H) Lipogenesis and ß-oxidation in liver and adipose tissue after 12 weeks of diet. (I-J) Plasma NEFA concentrations and liver triglycerides after
12 weeks of diet. Values are presented as mean ± SEM for n = 6–8; *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0136364.g002
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was no significant difference in the hepatic glucose production rate during the HIEC (Fig 4C),
the degree to which insulin stimulated the rate of glucose uptake by peripheral tissues (primar-
ily muscle and adipose tissue) was significantly elevated in guar gum-fed mice (Fig 4D). These
data were normalized for BW. Without BW correction, glucose-infusion rate and glucose
uptake remained significantly increased in guar gum-fed mice whereas hepatic glucose produc-
tion was significantly decreased compared to control-fed mice (S2A–S2C Fig), suggesting that
increased hepatic insulin sensitivity may also contribute to improved glucose handling.
Guar gum and cecal SCFAs increase plasma GLP-1 concentrations
In contrast to dietary SCFA-supplementation [13], guar gum did not only enhance insulin-
stimulated glucose metabolism, but it also decreased basal plasma glucose concentrations and
enhanced glucose tolerance (Figs 3 and 4). Together this suggests that there might be an addi-
tional factor, besided PPARγ repression, that improved glucose metabolism in guar gum-fed
mice. The colonic hormones peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) both reg-
ulate peripheral glucose metabolism [29,30]. PYY reinforces the insulin action on glucose dis-
posal in muscle and adipose tissue [29] and GLP-1 increases peripheral glucose-mediated
glucose uptake independently of hyperinsulinemia [30,31]. Guar gum feeding increased the
cecal mRNA expression and plasma concentration of GLP-1, whereas no effect was observed
on PYY (Fig 5A–5C).
Colonic SCFAs stimulate GLP-1 secretion and mice lacking the free fatty acid receptor
(Ffar) 2 showed reduced SCFA-triggered GLP-1 secretion and a parallel impairment of glucose
tolerance [32,33]. Guar gum also increased cecal mRNA expression of the SCFA receptor Ffar2
(Fig 5D). Therefore, we wondered if cecally supplemented SCFAs were capable of inducing
GLP-1 expression. To investigate this, we infused each individual SCFA directly into the cecum
of conscious, unrestrained mice that were fed the HFD without guar gum. We infused each
Fig 3. Guar gum increases insulin and glucose sensitivity. (A-B) Blood glucose and insulin concentrations upon a 4h fast after 12 weeks of diet. (C)
HOMA-IR was calculated from fasted glucose and insulin levels after 12 weeks on diet. (D) Insulin tolerance tests were performed on mice for 11 weeks on
their respective diets upon a 4h fast. (E) After 11 weeks on their respective diets an intraperitoneal glucose tolerance test was performed in mice that were
fasted overnight for 9h. Values are presented as mean ± SEM for n = 6–8; *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0136364.g003
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SCFA at the same rate and this rate was based on the recommended intake of dietary fiber for
humans (see Materials and Methods). Infusing SCFAs resulted in an increase in cecal concen-
tration of the infused SCFA without altering the concentrations of the other SCFAs (Fig 6A).
All three SCFAs increased the cecal mRNA expression of Ffar2 (Fig 6B). However, only acetate
and propionate infusion increased cecal GLP-1 mRNA expression and plasma concentration,
whereas cecal PYY mRNA expression and plasma concentration did not respond to any of the
three SCFA infusions (Fig 6B–6D). Together, these data suggest that guar gum increases
peripheral glucose disposal at least partially by enhancing GLP-1 secretion, mediated through
the cecal or colonic SCFAs acetate and propionate.
Discussion
We demonstrated that guar gum protects against HFD-induced obesity and insulin resistance
through the same signaling cascade in liver and adipose tissue as supplemented SCFAs. In
addition, guar gum exerts improved peripheral glucose handling, which is at least partially
mediated by the SCFA-induced colonic hormone GLP-1.
The anti-obesogenic effect of guar gum observed in the present study is in agreement with
earlier studies that showed that guar gum can prevent and reverse body weight gain in rodents
and humans [6,7,34]. Recently, we showed that the dose-dependent amelioration of the meta-
bolic syndrome by guar gum correlates with in vivo SCFA uptake fluxes by the host, suggesting
that the physiological effects of guar gum are primarily mediated by SCFAs that are taken up
Fig 4. Guar gum enhances peripheral glucose handling. (A) Average blood glucose concentrations during basal and hyperinsulinemic-euglycemic
clamps (HIEC) conditions after 12 weeks of diet. (B) Average glucose infusion rates needed to maintain euglycemic conditions. (C-D) Hepatic glucose
production and peripheral glucose disposal rate during HIEC conditions. Values are presented as mean ± SEM for n = 6–8; *p<0.05, **p<0.01, ***p<0.001
Guar gum vs. control.
doi:10.1371/journal.pone.0136364.g004
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by the host [10]. In addition, we showed that SCFAs protect against the metabolic syndrome
via a signaling cascade that involves PPARγ repression and AMPK activation [13]. Here we
demonstrate that guar gum supplementation works in the same way as SCFAs in the protection
against HFD-induced obesity and insulin resistance, namely by repressing PPARγ expression,
subsequently increasing mitochondrial UCP2 expression and AMP/ATP ratio, leading to the
activation of AMPK and culminating in enhanced fatty-acid oxidation in both liver and adi-
pose tissue. We note that—unlike corn starch–guar gum is only taken up after bacterial fer-
mentation. Acetic acid, the most abundant bacterial product, however, has the same C:H:O
ratio as carbohydrates and its oxidation, therefore, results also in the same respiratory exchange
ratio. Thus, the decreased RER in the guar-gum fed mice is most likely due to genuine long-
chain fatty-acid oxidation. The fact that guar gum elicits the same molecular and physiological
response as SCFA, further corroborates the notion that absorbed SCFAs are the main molecu-
lar mediators of the beneficial effects of guar gum on the metabolic syndrome.
Guar gum supplementation decreases fasting plasma glucose levels in healthy, type 1 and
type 2 diabetic humans but a clear mechanism has been lacking so far [4,5,35,36]. Here we
demonstrate that guar gum decreases plasma glucose levels by increasing the rate of glucose
clearance by peripheral tissues. Dietary SCFA supplementation elicited no effect on basal
plasma glucose levels and glucose tolerance [13], while we show here that guar gum has an
effect on glucose metabolism. This may be explained by the fact that SCFAs produced by cecal
bacterial fermentation of dietary fibers appear in the cecum, while orally ingested SCFAs are
absorbed in the small intestine and do not reach the cecum (S3A and S3B Fig). This is likely to
Fig 5. Guar gum increases colonic GLP-1 expression. (A) Cecal mRNA expression of PYY and GLP-1 were assessed by qPCR after 12 weeks of diet.
(B-C) Plasma PYY and GLP-1 concentrations after 12 weeks of diet. (D) Cecal mRNA expression of Ffar2 was assessed by qPCR after 12 weeks of diet.
Values are presented as mean ± SEM for n = 6–8; ***p<0.001.
doi:10.1371/journal.pone.0136364.g005
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affect their metabolic effects, since different hormonal and regulatory responses are triggered
in the different places in the gastrointestinal tract [37]. Consistently, we found increased
plasma levels of GLP-1 in mice supplemented with guar gum or cecally infused acetate or pro-
pionate (Figs 5 and 6), but not with orally ingested SCFAs (S3C Fig). GLP-1 has been shown to
increase peripheral glucose metabolism independently of hyperinsulinemia [38–40], which is
consistent with our results that show that guar gum mainly acts on peripheral tissues and that
orally ingested SCFAs did not affect basal glucose metabolism [13]. In addition, we show that
unlike acetate and propionate, butyrate does not induce GLP-1 expression when infused
directly into the cecum. This selective effect on GLP-1 is in agreement with the result that
SCFAs increase GLP-1 through Ffar2 activation [32], which has a preference for acetate and
propionate [41,42].
Apart from guar gum there are many other different dietary fibers that elicit benificial
effects in healthy and metabolic syndrome patients [43–45]. As most of these fibers also
increase cecal or fecal SCFAs [9,43], we speculate that their effects are mediated by SCFAs as
well. But, since cecal and fecal SCFA concentrations do not necessarily reflect their uptake
rates [10], it is difficult to compare these studies directly. Along similar lines, we conclude here
that the guar gum-induced effects are primarily mediated by the SCFAs, but it is possible that
additional metabolites are involved. The gut microbiota produces a wide range of other metab-
olites that have potential biological functions in host energy metabolism [46]. Various dietary
modulations alter the composition of the gut microbiota and, subsequently, the host metabolic
phenotype and disease risk [47,48].
Fig 6. Cecal acetate and propionate increase GLP-1 expression. (A) Cecal SCFA concentrations after 6h cecal SCFA infusion in mice fed HFD without
guar gum for 6 weeks. (B) After 6h cecal SCFA infusion cecal mRNA expression of Ffar2, PYY and GLP-1 were assessed qPCR. (C-D) Plasma PYY and
GLP-1 concentrations after 6h cecal SCFA infusion. Values are presented as mean ± SEM for n = 6–8; *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0136364.g006
Guar Gum Protects against the Metabolic Syndrome through SCFAs
PLOSONE | DOI:10.1371/journal.pone.0136364 August 20, 2015 11 / 14
Overall, this study provides novel molecular insights into the beneficial effects of guar gum
on the metabolic syndrome and strengthens the potential role of guar gum as a dietary-fiber
intervention.
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